Clinical Research Directory
Browse clinical research sites, groups, and studies.
Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
Sponsor: Charite University, Berlin, Germany
Summary
Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy. The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.
Official title: Pattern Recognition of Immune Cells in Atopic Dermatitis Patients Receiving Dupilumab
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
25
Start Date
2019-10-01
Completion Date
2026-12-31
Last Updated
2024-08-21
Healthy Volunteers
No
Conditions
Interventions
not applicable, observational study
Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
Locations (1)
Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin
Berlin, Germany